Physician profile
Nicholas Poellinger
NPI 1013593532
$1,860.47
in general payments reported to CMS, 2019-2025
16 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $249 · 2024: $1,231 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.24 |
| Education | $166.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $306.37 | 2023-2025 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $209.82 | 2024 | Uptravi, Opsumit |
| Atricure, INC. | $199.94 | 2024 | |
| Edwards Lifesciences Corporation | $181.08 | 2024 | |
| Bridgebio Pharma, INC. | $145.45 | 2025 | Attruby |
| Irhythm Technologies, INC. | $123.53 | 2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.43 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $118.24 | 2024 | Nexletol |
| Abiomed | $114.76 | 2023-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $107.10 | 2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.71 | 2023-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $58.40 | 2024-2025 | |
| Shockwave Medical, INC | $18.58 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $18.45 | 2025 | Cardiomems |
| Janssen Pharmaceuticals, INC | $18.08 | 2024 | Xarelto |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.53 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Poellinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.